Indication of a role of plasminogen activator inhibitor type 1 in protecting murine fibrosarcoma cells against apoptosis

Summary In a number of cancer types high tumor tissue levels of plasminogen activator inhibitor type 1 (PAI-1) protein are strongly associated with shorter cancer patient survival. This association has been intriguing since PAI-1 is known to inhibit urokinase plasminogen activator (uPA) that converts plasminogen to plasmin, which is actively involved in tumor progression and invasion. In order to further explore the biological role of PAI-1 in cancer, we have prepared fibroblasts from PAI-1 gene deficient mice and from their wild type littermates. From these fibroblasts fibrosarcoma cell lines were established and characterized. Both types of fibroblasts underwent spontaneous transformation as indicated by aneuploidy, immortalization, clonogenicity in soft agar and tumor formationin vivo. While both PAI-1 deficient and PAI-1 expressing cell lines showed similar proliferation ratesin vitro, cells devoid of PAI-1 were significantly more sensitive to apoptotic stimuli. When inoculated subcutaneously into nude mice PAI-1 expressing cells rapidly established tumors, while PAI-1 deficient cells had a significantly longer lag-phase before they started to grow (p<0.0001). The present study suggests that PAI-1,besides its uPA inhibiting function, has a role in cancer progression by protecting tumor cells from undergoing apoptosis.

[1]  J. S. Rao,et al.  Prognostic significance of proteolytic enzymes in human brain tumors , 2005, Journal of Neuro-Oncology.

[2]  B. Sobel,et al.  Inhibition of apoptosis and caspase‐3 in vascular smooth muscle cells by plasminogen activator inhibitor type‐1 , 2004, Journal of cellular biochemistry.

[3]  Manfred Schmitt,et al.  Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer , 2004, Thrombosis and Haemostasis.

[4]  F. Blasi,et al.  The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.

[5]  P. Andreasen,et al.  Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. , 2004, Thrombosis and haemostasis.

[6]  D. Lawrence,et al.  Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. , 2003, Current pharmaceutical design.

[7]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[8]  N. Brünner,et al.  Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * , 2003, Molecular & Cellular Proteomics.

[9]  A. Scorilas,et al.  Significance of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1 (PAI-1) Expression in Human Colorectal Carcinomas , 2002, Tumor Biology.

[10]  W. Berdel,et al.  The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells. , 2002, Journal of cell science.

[11]  L. Kjøller.  The Urokinase Plasminogen Activator Receptor in the Regulation of the Actin Cytoskeleton and Cell Motility , 2002, Biological chemistry.

[12]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[13]  A. Nerlich,et al.  Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). , 2001, International journal of oncology.

[14]  Nils Brünner,et al.  The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin , 2001, The Journal of cell biology.

[15]  F. Castellino,et al.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. , 2000, Cancer research.

[16]  P. Declerck,et al.  Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis , 2000, British Journal of Cancer.

[17]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[18]  H. Pappot.  The plasminogen activation system in lung cancer — with special reference to the prognostic role in “non‐small cell lung cancer” , 1999, APMIS. Supplementum.

[19]  J. Foekens,et al.  Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[20]  B. Nielsen,et al.  Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  E. Rosenthal,et al.  Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. , 1998, Cancer research.

[22]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[23]  K. Nakagawa,et al.  Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. , 1998, Oral oncology.

[24]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[25]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[26]  K. Danø,et al.  The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. , 1995, Biological chemistry Hoppe-Seyler.

[27]  P. Quax,et al.  Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. , 1994, Gastroenterology.

[28]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. , 1993, The Journal of clinical investigation.

[29]  H. Hansen,et al.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. , 1993, British Journal of Cancer.

[30]  N. Brünner,et al.  The nude mouse as an in vivo model for human breast cancer invasion and metastasis. , 1993, Breast Cancer Research and Treatment.

[31]  M. Rudnicki,et al.  Simplified mammalian DNA isolation procedure. , 1991, Nucleic acids research.

[32]  L L Vindeløv,et al.  A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. , 1990, Cytometry.

[33]  D. Goldenberg,et al.  In vivo horizontal oncogenesis by a human tumor in nude mice. , 1982, Proceedings of the National Academy of Sciences of the United States of America.